Table 3.
Clinical trials of lipid nanoparticle–mRNA vaccines for lung viral infectious diseases.
| Name | Funding Source | Disease | Encoded Antigen | Administration Route | Stage | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|
| mRNA-1440 (nucleoside-modified) | Moderna Therapeutics | Influenza H10N8 | Haemagglutinin | i.m. | Phase I | NCT03076385 |
| mRNA-1851 (nucleoside-modified) | Moderna Therapeutics | Influenza H7N9 | Haemagglutinin | i.m. | Phase I | NCT03345043 |
| mRNA-1273 (perfusion-stabilized S protein mRNA vaccine) | Moderna Therapeutics/National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19 | Spike | i.m. | Phase III | NCT04470427 |
| BNT162 (3 LNP-mRNA vaccines) |
BioNTech/Pfizer | COVID-19 | Spike | i.m. | Phase III | NCT04537949 |
| BNT162b2 | Pfizer | SARS-CoV-2 | Spike | i.m. | Phase III (EUA and CMA) | NCT04368728 |
| CVnCoV | CureVac AG | SARS-CoV-2 | Spike | i.m. | Phase III | NCT04652102 |
| ARCT-021 | Arcturus Therapeutics | SARS-CoV-2 | Spike | i.m. | Phase II | NCT04728347 |
| mRNA-1345 | Moderna | RSV | F glycoprotein | i.m. | Phase I | NCT04528719 |
EUA; emergency use authorization, CMA; conditional marketing authorization, i.m.; intramuscular, SARS-CoV-2; severe acute respiratory syndrome coronavirus 2, RSV; respiratory syncytial virus.